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ABSTRACT 
Objective: The intent to prepare and evaluate Linezolid in-situ gel in the treatment of periodontitis.  
Methods: pH-sensitive in-situ gel was formed by the cold method using a varying concentration of the drug, carbopol 934P and hydroxypropyl 
methylcellulose (HPMC) and carbopol 934P and sodium carboxy methylcellulose (CMC) (1:1,1:1.5,1:2,1:2.5). An optimized batch was selected based 
on gelling time and gelling capacity. The prepared in-situ gels were evaluated for appearance, pH, gelling capacity, viscosity, in vitro release studies, 
rheological studies, and finally, was subjected to drug content estimation and antibacterial activity test. 
Results: FTIR study shows drug and physical mixture were compatible with each other. The rheology of formulated in-situ gel exhibited a 
pseudoplastic flow pattern. this may be because when polymer concentration was increased the prepared formulations become more viscous and in 
turn delayed the drug release and from the prepared formulation, LF4 and SF4 have polymer concentrations i. e, 0.9% carbopol and sodium CMC 
showed drug release up to 12 h.  
Conclusion: When carbopol is appropriately mixed with other suitable polymers it forms an in-situ gel-forming system that was substantiated 
by the property to transform into stiff gels when the pH is increased. The in-situ gel was prepared using a combination of carbopol-HPMC and 
carbopol-Na CMC The formulations LF1 to SF4 showed high linearity (R2 = 0.490-0.682), indicating that the drug was released from the 
prepared in-situ gel by the diffusion-controlled mechanism. Thus, the formulation of batches LF4 and SF4 containing carbopol: HPMC and 
carbopol: NaCMC in 1:2 ratios were considered as optimum formulation based on optimum viscosity, gelling capacity and to extend the in vitro 
drug release. 
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INTRODUCTION 
Periodontal diseases are mainly of bacterial etiology in the 
initiation and progression of periodontal diseases. The treatment 
goal is in the reduction of infection and inflammation, which can 
be achieved using adjunctive drugs such as anti-microbial agents 
and anti-inflammatory agents [1]. The World Health Organization 
(WHO) has reported that antibiotic resistance causes about 
700,000 deaths each year and that this number will reach 10 
million globally by 2050 if no effective intervention becomes 
available (WHO, 2014) [2]. Linezolid is a new class of antibiotic, 
the oxazolidinones, which is used in the therapy of infections 
caused by aerobes and anaerobes susceptible organisms 
methicillin and vancomycin-resistant [3]. It has been 
demonstrated that Linezolid is superior to vancomycin in terms of 
antipyretic and anti-inflammatory properties [4]. A variety of 
pharmacological agents has been studied in the therapy of 
periodontitis. These include anti-inflammatory drugs, biphonates, 
and antimicrobials. Controlled local delivery of the antimicrobial 
anti-inflammatory agents was consequently developed and are 
effective in the concentration of the drug in the periodontal pocket 
for prolong periods than systemically delivered methods [5]. 
Articulated pH-triggered system of in-situ gel containing carbopol 
as in situ gel-forming system has a property of transforming sol 
into a gel when the pH is increased. Viscosity improver Hydroxy 
Propyl Methyl Cellulose (HPMC) is added to achieve sustained 
drug release in periodontal pocket [6]. So intent is to develop and 
deliver new treatments for periodontal disease that target drug-
resistant bacteria, which caused the big threat. Hence challenge 
was to articulate Linezolid in-situ periodontal gel which sustains 
for a longer duration of action by remedying periodontal disease. 
MATERIALS AND METHODS 
Drug characterization study 
Infra-red (IR) spectroscopy study: an fourier transform  
IR spectrum of the Linezolid and polymers was obtained on a 
Shimadzu Corporation, Japan. A multi particulate form drug 
prepared with Potassium bromide (Spectroscopic Grade) using 
hydraulic pellet press at a pressure of 7-10 tones. The scanning 
range was 400 to 4000 cm-1 and the resolution was 1 cm [6]. 
Preparation of in-situ gel procedure 
In-situ gels were formed by cold method using varying concentration 
of drug, carbopol 934P and hydroxypropyl methylcellulose (HPMC) 
(LF1, LF2, LF3 and LF4) and carbopol 934P and sodium carboxy 
methyl cellulose (NaCMC) (SF1=1:1, SF2=1.15, SF3=1:2, SF4=1:2.5). 
Optimized batch was selected based on gelling time and gelling 
capacity. Formulations containing drug and polymer ratios are 
coded as LF1=1:1, LF2=1.15, LF3=1:2, LF4=1:2.5 SF1=1:1, SF2=1.15, 
SF3=1:2, SF4=1:2.5. Experimentation was done using different 
concentrations of drug and polymers to obtain the desirable 
concentration of formulation for the gelling. Dispersion of NaCMC 
and carbopol 934P was added to aqueous solution of sodium 
citrate(0.19% w/v) while stirring heated to 92 °C then cooling it to 
under 38 °C then calcium chloride (0.06% w/v) was mixed into the 
solutions. Linezolid was dissolved in propylene glycol separately. 
Mixture of drug and propylene glycol was added in the polymeric 
solution. The mixture was placed on magnetic stirrer for thorough 
mixing. Methylparaben (MP) and propylparaben (PP) were added as 
preservatives. Finally the triethanolamine was added to neutralize 
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in-situ gel and air bubbles were removed from ready to use solution 
by allowing it to stand for 2 h [7]. 
 
 
Fig. 1: Manufacturing steps involved in in-situ gel technique 
 
Evaluation of in-situ gel 
Appearance 
Formulated preparations clarity was observed by visual inspection. 
Determination of pH 
pH of formulations was determined using pH digital meter 
instrument  
Gelling capacity 
The gelation capacity was found by the visual method by using dye 
formulated solutions were colored. Gelation capacity was 
determined by placing 3 ml of pH 6.8 phosphate buffer in a 10 ml 
test tube ad maintained at body temperature. 1 ml of colored 
formulated preparation was added to the phosphate buffer. As the 
formulation mixed with prepared phosphate buffer, the formulation 
was quickly transformed into gel [8].  
Gelation temperature 
Magnetic bead and 10 ml of sample solution were taken in a vial 
which was kept in a water bath. The heating of the solution was 
done by stirring at 1°/min. Gelation was considered when the 
magnetic bead stopped moving at a particular temperature and 
noted down as gelation temperature [8]. 
Gelation time 
Test tube containing 2 ml of linezolid in-situ gel was kept in a water 
bath and the temperature was raised slowly by heating and allowed 
to stand to equilibrate for fresh settlement. Gelation of the sample 
was examined; gelation took place when the meniscus upon tilting 
through 90° would no longer move [8]. 
Spreadability 
The formulated gel and its ability to spread was determined for 48 h 
after preparation, it is measured by spreading one gram gel in 
between plates made up of glass for 1 min. The weight of the top 
glass plate was standardized at 125g. The mathematical formula 
expressed as:  
S = M*L/T 
Where L is the length of the glass slide, M is mass weight tied up to 
the slide, and T is the time taken. Homogeneity of the formulated gel 
was inspected visually [8]. 
Syringeability 
All formulated gel was transferred into an identical 5cc (cubic 
centimeter) plastic syringe with a 21 gauge needle to constant 
volume (1 ml). The formulated gel was easily pass through from the 
syringe considered as pass and if not pass through as fail [9]. 
Drug content estimation 
One ml of the different formulated in-situ gel was added to a vial 
containing 5 ml of distilled water and equilibrated at 37 °C and 
the formation of the gel was observed visually. Once gel formed, 
formulations were taken into dialysis tubes. These tubes were 
placed in a transparent cup contained 50 ml of distilled water 
and formulated gel was dialyzed for half a minute at 50 rpm and 
this medium was changed with new distilled water to confirm 
complete removal of the entrapped drug. The concentration of 
all these solutions was found spectrophotometrically at 250 nm, 
after acceptable dilution and filtration using distilled water as 
blank [9].  
Viscosity and rheological studies 
To determine the rheology of Linezolid in-situ gel spindle number 
LC of Brookfield digitalized viscometer was used. The in-situ gel 
viscosity was determined at various angular velocities at 25 °C. A 
distinctive run comprised of changes in the angular velocity from 10 
to 60 rpm. The viscosity measures were performed prior to gelling 
and after gelling [9]. 
In vitro release kinetics studies 
The kinetic study of drug release from Linezolid in-situ gel was 
interpreted, after obtaining data from in vitro release of drug study 
and it was fit into various standard models including first and zero 
orders. The r2 values obtained by comparison and the better model 
fitted was selected [10]. 
In vitro diffusion studies 
The release of drug profile from Linezolid in-situ gel was performed 
by using Franz diffusion cell (capacity 25 ml). One gram of linezolid 
formulated in-situ gel was placed in the donor compartment and 25 
ml of pH 6.8 dissolution medium (simulated salivary pH) in the 
receptor compartment. In the middle of the receptor and donor 
compartment chicken cheek, the mucous membrane is placed. Sols 
were added to it from above so that when it comes in contact with 
the saliva, fluid gets transformed into gel form. This assembly was 
kept on the magnetic stirrer, which is controllable by thermostatic 
manner. The temperature of the medium was kept at 37 °C±0.5 °C. 1 
ml of the sample was removed at prior determined rate 0.5 h to 12 h 
interval and a fresh medium of the same volume was replaced. 
Removed samples were diluted to 10 ml in a volumetric flask with 
the same buffer medium and analyzed using an Ultraviolet 
spectrophotometer at 250 nm using blank. The drug content was 
determined by using an equation obtained from the standard curve. 
The percentage of cumulative drug release (% CDR) was calculated 
[9-16]. 
Antibacterial activity 
The growth of microbial bacteria was measured by the 
concentration of antibiotics present and comparison of this with 
standard preparation of antibiotic that produced by known 
concentration. The microbiological assay carried out by serial 
dilution method was employed [12, 13]. Test organism 
recommendation for linezolid is Staphylococcus aureus [14]. 
RESULTS AND DISCUSSION 
Drug-polymer interaction studies 
There is no significant interaction was observed between pure drug 
and polymer mixture from FTIR spectrum are in fig. 1 and 2. 
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FTIR spectrum of pure drug of linezolid 
 
Fig. 2: FTIR spectrum of the linezolid 
 
FTIR spectrum of drug and polymeric mixture  
 
Fig. 3: FTIR spectrum of the linezolid and polymers 
 
Appearance 
All formulated in-situ gel is shown clearness.  
Determination of pH  
The measured pH in meter was found to be in the range of 4 to 7.5, 
which is the required range to formulate in-situ gel. The pH of 
formulated linezolid in-situ gel was adjusted in the range 6.2 to 7 by 
using triethanolamine. The measured pH is shown in table 2. 
Gelation temperature and gelation time 
For the selection of a proper concentration of polymers (carbopol 
and sodium CMC), various solutions of polymers of different 
concentrations ranging from 0.6-0.9% were prepared and optimized 
concentration was prepared based on gelation temperature and 
gelation time. The temperature of gelation ranging from 34 to 37 °C 
is considered as suitable for in-situ gel in periodontal disease, which 
is nothing but gel should be in solution form at normal temperature 
and the oral cavity form a gel phase. If the temperature of gelation is 
less than 33 °C of the solution, then gelation occurs at room 
temperature, which leads to difficulty in administering the 
formulation. If the gelling temperature is higher than 35 °C of in-situ 
gel formulation, the gel stays in a liquid form at body temperature, 
leads to leakage of formulation from the periodontal pocket. The 
gelation temperature of linezolid in-situ gel was found by visual 
inspection method within the range of 34 to 37 °C. The temperature 
of gelation was dependent on the polymer concentration used; the 
results are depicted in table 2. Formulation LF4 and SF4 showed 
rapid gelation i.e. at 5.36 min and 8.28 min, respectively, as this 
formulation contains the highest concentration of polymers. This 
study revealed that when polymer concentration increases, there 
was a decrease in gelation time and gelation temperature. 
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Formulations LF1, SF1 and SF2 were discarded from the study, as 
these formulations do not form gel up to 45 °C. Formulation LF4, 
containing 0.9 % carbopol showed the lowest gelation time i.e. 5.37 
min compared to formulation SF4 containing the same 
concentration of Na CMC i.e. 8.28. In our study, formulations 
containing carbopol showed less gelation time compared to 
formulations containing sodium CMC.  
Drug content estimation 
All formulations of Linezolid in-situ gel were analyzed for drug 
content spectrophotometrically at 250 nm. Prepared in-situ gels 
exhibited fairly uniform drug content. This ensures an intended drug 
delivery to the site after administration. All prepared in-situ gels 
formulations’ drug content as shown in table 4 and found to be in 
the range of 96.80 to 98.42 %. the data depicts there is no significant 
loss of drug in any formulation during manufacture.  
Syringeability 
Syringeability test showed that prepared in-situ gel formulations 
were easily injectable at room temperature (25 °C), through 21 
gauge needle. This facilitates the injection of sol directly into the 
periodontal pocket. 
 
Table 1: Characteristics of various formulations 




Drug content (%) 
LF1 1:1 6.8 46 No gelation -- 97.54 
LF2 1:1.5 6.5 37 Gelation after few minutes 12.45 96.80 
LF3 1:2 6.2 35 Immediate and stable for few hours 9.22 96.99 
LF4 1:2.5 6.2 34 Immediate and stable for extended period 5.37 98.42 
SF1 1:1 6.9 45 No gelation -- 98.08 
SF2 1:1.5 7.5 46 No geiation -- 97.44 
SF3 1:2 6.5 37 After few minutes 11.31 97.91 
SF4 1:2.5 7.1 35 Immediate and stable for few hours 8.28 96.97 
 
Spreadability studies 
The spreadability studies results shown in table 2 revealed that 
spreadability decreases when polymers concentration of in-situ 
gel formulation increases [17]. Table 2 depicts the data that 
indicates that the increase in the concentration of any of the 
gelling agents in the in-situ gels formulations decreases its 
spreadability. Shorter the time taken to separate 2 slides better 
will be the spreadability. The spreadability of all prepared in-situ 
gel formulations was found to be in the range of 12.70-21.04 
gm·cm/sec. Formulation LF4 containing the highest concentration 
of carbopol was less spreadable (12.70 gm·cm/sec) when 
compared to the same concentration of Sodium CMC i.e. 
formulation SF4 (15.00 gm·cm/sec). 
  
Table 2: Spreadability studies results 
Formulation Weight tied to the upper slide (g) Length of the glass slide (cm) Time (sec) Spreadability (gm·cm/sec) 
LF1 125 8.3 60 17.29±0.3 
LF2 125 7.8 60 16.25±0.1 
LF3 125 7.4 60 15.41±0.2 
LF4 125 6.1 60 12.70±0.3 
SF1 125 10.1 60 21.04±0.2 
SF2 125 8.6 60 17.91±0.1 
SF3 125 7.9 60 16.45±0.3 
SF4 125 7.2 60 15.00±0.2 
(Values represent mean±SD, n=3) 
 
Viscosity study of in-situ gel formulations 
The viscosity of prepared linezolid in-situ gel shear rate was increased 
as the viscosity of gel decreased in both prior gelling and after gelation 
cases. Results of viscosity studies showed that viscosity of prepared 
formulation was drastically increased to a 4-fold increase in the 
viscosity of prepared after gelation. The viscosity of the prepared in-
situ gel was the concentration-dependent of the gel base; on increasing 
the concentration of polymer, the viscosity of the gel was increased 
(table 4). Rheological evaluation of selected formulation exhibited 
pseudoplastic flow before and after gelation (fig. 4 and 5). Further, the 
formulations were liquid neutral pH and underwent rapid gelation 
when the pH was at 6.8. The viscosity of the prepared formulation 
contributed to the product adhesiveness, reflecting the importance of 
product rheology on this parameter. Additionally, the gel formed in-
situ should maintain its integrity without dissolving or eroding for a 
prolonged period. These results are in accordance with the finding of 
Biswas and Yellanki et al. [18, 19]. 
 
Table 3: Viscosity before gelation 
Viscosity before gelation (cps) 
Formulation 
RPM LF1 LF2 LF3 LF4 SF1 SF2 SF3 SF4 
10 985±2.2 1055±2.4 1070±2.6 1127±2.3 976±2.5 1020±2.0 1065±2.3 1090±2.6 
20 750±1.9 765±0.2 786±1.6 795±1.4 730±1.7 750±1.1 770±1.3 805±1.2 
30 581±1.4 595±1.7 600±1.3 608±1.5 560±1.2 575±1.1 580±1.4 610±1.5 
40 334±1.2 343±1.3 354±1.2 369±1.5 325±1.7 310±1.3 340±1.5 385±1.3 
50 177±1.5 165±1.8 180±1.4 206±1.1 160±1.3 158±1.2 170±1.6 206±1.4 
60 98±1.5 105±1.2 112±1.4 117±1.3 102±1.5 110±1.4 120±1.2 125±1.6 
(Values represent mean±SD, n=3) 
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Fig. 4: Rheological study of prepared formulation before gelling 
 
Table 4: Viscosity after gelation 
Viscosity after gelation (cps) 
Formulation 
RPM LF1 LF2 LF3 LF4 SF1 SF2 SF3 SF4 
10 3880±1.5 4068±1.3 4225 4633±1.3 3760 4015±1.3 4460±2.6 4570±1.8 
20 2850±1.7 3387±2.6 3470 3550±2.6 2742 3260±1.6 3380±2.6 3430±1.3 
30 2270±1.3 2380±1.7 2450 2538±1.7 2229 2275±1.7 2348±1.3 2450±1.7 
40 1685±1.3 1610±1.6 1715 1761±1.3 1625 1570±1.2 1630±1.6 1690±1.6 
50 970±1.6 995±1.3 1025 1059±1.6 862 965±1.3 1015±1.3 1025±1.2 
60 565±1.3 530±1.3 505 487±1.5 575 560±1.4 546±1.3 520±1.3 
(Values represent mean±SD, n=3) 
 
 
Fig. 5: Rheological study of prepared formulation after gelation 
 
In vitro release kinetics studies 
• The obtained results of all the formulations were best described 
by the Higuchi release kinetics model, as the plots showed higher 
linearity (r2 = 0.994-0.996) in comparison to zero-order (r2 = 0.894-
0.912) and first-order (r2 = 0.917-0.942). The r2 values obtained, by 
comparison, the better model fitted was selected 
• The release exponent (n) value was obtained in the range of 1.16-
1.48, which suggest that formulated linezolid in-situ gel matched 
with Super-case II transport and the obtained (n) values are greater 
than 0.89 
In vitro diffusion study 
This study was performed for 12 h. During diffusion studies, the 
polymer concentration effect of in-situ gel formulated was carried 
out on release pattern. The CDR (cumulative drug released) 
percentage shown in fig. 9. Results showed the drug was decreased 
in formulated in-situ gel formulations when polymer concentration 
was increased this may be because the prepared formulations 
become more viscous which in turn delayed the release pattern of 
the drug from the prepared formulation. These outcomes are 
parallel to interpretations reported earlier by Parhi, Kalia, and 
Mekkawy et al. [20-22]. This release pattern of drug study reveals 
almost half of the drug discharges from all formulations within 4.0 h. 
The drug release from these gels was characterized by the first 
opening phase of high release up to 4.0 h and the rest of the drug 
was liberated at a slower rate in the next phase. This dual-phase 
drug pattern release is a distinctive feature of matrix diffusion 
kinetics. Formulation LF1, LF2, LF3, SF1, SF2, and SF3 showed 
almost 75% of drug discharges up to 6 hour, whereas formulation 
LF4 and SF4 with the highest polymer concentration that is 0.9% 
carbopol and sodium methylcellulose showed release of the drug up 
to 12 h, which might be due to higher viscosity and gelation capacity 
of these prepared formulations based on release studies, 
formulation LF4 and SF4 was selected for further studies. 
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Table 5: Values of release exponent and rate constant 
Formulation code Kinetics models Best fit 
model 
Drug release mechanism 
Zero order First order Higuchi Korsmeyer-peppas 
R2 R2 R2 R2 n 
LF1 0.873 0.905 0.970 0.682 1.018 Higuchi Super case II 
LF2 0.858 0.839 0.984 0.490 1.189 Higuchi Super case II 
LF3 0.821 0.656 0.983 0.604 1.088 Higuchi Super case II 
LF4 0.8580 0.885 0.994 0.547 1.012 Higuchi Super case II 
SF1 0.909 0.909 0.983 0.534 1.053 Higuchi Super case II 
SF2 0.847 0.796 0.975 0.520 1.083 Higuchi Super case II 
SF3 0.943 0.866 0.978 0.472 1.192 Higuchi Super case II 
SF4 0.851 0.894 0.987 0.680 1.005 Higuchi Super case II 
 
 
Fig. 6: Comparative zero order release profile of in-situ gel formulation 
 
 
Fig. 7: Comparative first order release profile of in-situ gel formulations 
 
Antibacterial activity 
The activity of three samples was tested for Minimum Inhibitory 
Concentration (MIC) against Staphylococcus aureus., and they are 
coded as X, Y, and Z. X = formulation LF1, Y = pure sample, Z = 
formulation SF4. 250μg concentration of Linezolid drug was added 
to the standard solution and sample solution. 13 Sterilized test tubes 
were numbered from 1 to 13. Linezolid 128 μg/ml of concentration 
and 1000 μl of the solution was transferred from tube no.1 to tube 
no.2 by mixing. In a similar manner tube, no.3 to tube no.10 
prepared to get various concentrations. The final two tubes each 
contain a thousand microliters of media named as media restrain 
and another tube as drug restrain. 10 microliters broth of the S. 
aureus was seeded into all the tubes except in negative control and it 
was kept in an incubator at 37 °C for up to one day to find its growth. 
Subsequently, 24 h later the incubated tubes were observed for 
growth inhibition and MIC calculated and finally, results were 
tabulated in table 6. 
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Fig. 8: Comparative higuchi release kinetics of in-situ gel formulations 
 
 
Fig. 9: The in vitro release profiles of linezolid in-situ gels 
 
Table 6: Antibacterial activity test-MIC 
Concentration in mcg/ml Turbidity in pure drug sample (standard) Turbidity in LF1 formulation Turbidity in SF4 formulation 
128 - - - 
64 - - - 
32 - - - 
8 - - - 
4 - - - 
2 + + + 
1 + + + 
0.5 + + + 
0.25 + + + 
MR - - - 
DR - - - 
PC + + + 
NC - - - 
MR = Media Restrain, DR = Drug Restrain, PC = Positive control, NC = Negativecontrol, (-) = no turbidity (inhibitory),+= turbidity (No inhibitory) 
 
The bactericidal sensitivity test for MIC was done by the serial 
dilution method. Finally, in drug-containing solutions of standard, 
sample, LF1, and SF4 formulations the Minimum Inhibitory 
Concentration was found to be 4 micrograms per ml and observed 
that it was in accordant with standard linezolid and no reduction in 
the prepared formulation efficaciousness. These results are in 
accordance with the finding of Hiremath SSP et al. [23]. The linezolid 
in-situ gel formulation is a viable alternative and target drug-
resistant bacteria which caused big threat for the treatment of 
periodontal disease. 
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CONCLUSION 
This study of the articulated pH-triggered system of in-situ gel 
containing carbopol as in situ gel-forming system has a property of 
transforming into a gel when the pH was increased and Viscosity 
improver HPMC is included to achieve a sustained drug release 
pattern in the periodontal pocket. The linezolid in-situ gel is a new 
treatment for periodontitis that targets drug-resistant bacteria 
which pose the greatest threat for the treatment was successfully 
formulated using carbopol as a gel base. This formulation has a 
viscosity contribution to the product adhesiveness, reflecting the 
importance of product rheology. This formulation imparts the 
release of the drug at the site of absorption, which may result in a 
higher concentration of drug at the local site. Hence, based on 
obtained results, it is concluded that the formulation 0.9% carbopol 
and sodium carboxy MC was envisaged as an optimized formulation 
and drug released for an extended period i.e. over and above 50% 
percent release of drug was up to 12 h this may lead to better 
patient compliance. This In-situ gel of linezolid could be a potential 
delivery system for clinical testing in periodontitis. Further, linezolid 
is a new class of antibiotics, which has clinical use in the treatment 
of infections caused by aerobes and anaerobes susceptible 
organisms’ methicillin and vancomycin-resistant. 
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